News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
The laboratory is equipped to perform high-volume diagnostic testing services
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Subscribe To Our Newsletter & Stay Updated
